Self-Regulation: Rare Cancers Patient Voice consultant says the pharma/patient interaction element of the code needs to be changed - but MA says it's just reflecting Therapeutic Goods Act requirements and welcomes a discussion.
Self-Regulation: Marketing agencies working with pharmaceutical companies in Australia say the Medicines Australia Code of Conduct is having a significant impact on their ability to provide a service for their clients.
Roche given FDA go-ahead in lung cancer
Roche has received approval to enter the second-line NSCLC race against BMS and MSD while Shire gains access to the pancreatic cancer market in Europe with Onivyde.
Time to come out of the closet - again
The public face of the pharmaceutical industry is often under discussion inside the industry itself, perhaps no more so than at present but do attempts to raise pharma's public profile in a positive way actually work?